"There is an innate ability to heal, and the therapist's job is to remove obstacles and create favorable conditions for healing."
- Dr. michael Mitheofer, medical monitor and clinical investigator for maps
With promising information showing a fast, safe and effective way of treating PTSD, we are excited to be one of the first clinics in the US to be offering this treatment in the near future.
MDMA-assisted psychotherapy is a revolutionary form of psychotherapy recently given approval by the FDA for limited public offering. It is a series of psychotherapy sessions over 3-6 months, including regular talk therapy preparation, integration sessions and MDMA-assisted sessions.
Phase 2 clinical trials have shown that MDMA can reduce fear and defensiveness, enhance communication and introspection, and increase empathy and compassion, enhancing the therapeutic process for people suffering from PTSD. MDMA produces effects which counteract avoidance and hyperarousal in the context of therapy. A combined treatment of MDMA and psychotherapy has proven to be especially vital to treating complex PTSD.
In MAPS’*completed Phase 2 trials with 107 participants, 61% no longer qualified for PTSD after three sessions of MDMA-assisted psychotherapy two months following treatment. At the 12-month follow-up, 68% no longer had PTSD. All participants had chronic, treatment-resistant PTSD, and had suffered from PTSD for an average of 17.8 years.
The Luminous Healing Center offers a innovative suite of trauma treatments designed to work in concert to promote rapid and lasting healing from psychological trauma.
We are incredibly excited to announce we will soon be offering MDMA-assisted psychotherapy for patients diagnosed with posttraumatic stress disorder (PTSD).
We are excited to be one of the few clinics in the United States with the ability to offer this treatment through an Expanded Access Program under the guidance of the Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA) and in collaboration with Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation (MAPS PBC).